SANTEN PHARMACEUTICAL CO., LTD. Patent applications |
Patent application number | Title | Published |
20160106757 | OPHTHALMIC SOLUTIONS - An ophthalmic formulation which is an aqueous solution of a prostaglandin derivative, the prostaglandin derivative being 16-phenoxy-15-deoxy-15,15-difluoro-17,18,19,20-tetranorprostaglandin F2 α or an isopropyl ester thereof, said prostaglandin derivative being contained in the aqueous solution as an active ingredient in a concentration of 0.00005 to 0.05 weight %, a nonionic surfactant which is polysorbate 80 in a concentration in the solution of 10 times or more to 100 times or less of the prostaglandin derivative and an antioxidant in an amount sufficient to inhibit decomposition of the prostaglandin derivative. | 04-21-2016 |
20160022648 | THERAPEUTIC AGENT FOR MEIBOMIAN GLAND DYSFUNCTION - A compound represented by the formula (1): | 01-28-2016 |
20150291560 | 2-[[[2-[(HYDROXYACETYL)AMINO]-4-PYRIDINYL]METHYL]THIO]-N-[4-(TRIFLUOROMETH- OXY)PHENYL]-3-PYRIDINECARBOXAMIDE BENZENESULFONATE, CRYSTAL OF SAME, CRYSTAL POLYMORPH THEREOF, AND METHODS FOR PRODUCTION THEREOF - In the course of developing 2-[[[2-[(hydroxyacetyl) amino]-4-pyridinyl]methyl]thio]-N-[4-(trifluoromethoxy) phenyl]-3-pyridinecarboxamide(compound A), there are the multiple problems: 1) compound A or its salt is difficult to be recrystallized, the storage stability largely differs depending on the kind of the salt, and it is very difficult to obtain a salt of compound A having excellent storage stability; 2) in a crystallization process of compound A, it is very difficult to control a crystal polymorph, and 3) compound A (free body) causes mineral deposition in the stomach when it is orally administered repeatedly. For solving these problems, we made examination focusing on the kind of the salt and, as a result, found that 1) benzenesulfonate of compound A does not decompose by light, humidity and other factors in a 1-week preliminary stability test (severe test), and has no problem in its storage stability, 2) a method of selectively producing two kinds of crystal forms of benzenesulfonate of compound A, and that 3) no mineral deposition in the stomach is observed even after a 4-week repeated oral administration. | 10-15-2015 |
20150196541 | PHARMACEUTICAL FORMULATIONS COMPRISING A PYRIDYLAMINOACETIC ACID COMPOUND - Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl(6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof. | 07-16-2015 |
20150125395 | METHOD FOR CHANGING CONDITION OF EYELID BY ADMINISTERING COMPLETE FREUND'S ADJUVANT - A method for changing a condition of an eyelid of a mammal excluding a human, a model animal for evaluating a therapeutic or prophylactic effect against an eyelid disease obtained by the method, a method for producing the model animal, a method of screening using the model animal and a substance having a therapeutic or prophylactic effect against an eyelid disease selected by the method of screening, and a therapeutic or prophylactic agent against an eyelid disease containing the substance as an active ingredient. | 05-07-2015 |
20150125394 | METHOD FOR CHANGING CONDITION OF EYELID OF HAIRLESS ANIMAL - A method for changing a condition of an eyelid of a hairless animal, a model animal for evaluating a therapeutic or prophylactic effect against an eyelid disease obtained by the method, a method for producing the model animal, a method of screening using the model animal and a substance having a therapeutic or prophylactic effect against an eyelid disease selected by the method of screening, and a therapeutic or prophylactic agent against an eyelid disease containing the substance as an active ingredient. | 05-07-2015 |
20150073005 | COMPOSITION FOR HAIR GROWTH - To provide a composition for hair growth (hair growth agent) which has high hair growing effects and can be used for prevention or treatment of alopecia. The composition for hair growth comprises as an active ingredient at least one member selected from the group consisting of a compound represented by the formula (1) and a salt thereof. In the formula, R is a carboxy group or an alkoxycarbonyl group. | 03-12-2015 |
20150011518 | NON-AQUEOUS LIQUID COMPOSITION - A drug-dissolved non-aqueous liquid composition containing a drug, dioleylphosphatidylcholine, tocopherol and an organic solvent, wherein the blend concentration ratio between the dioleylphosphatidylcholine and the tocopherol falls within the range of 75/25 to 25/75, the blend concentration of the dioleylphosphatidylcholine falls within the range of 15 to 85% (w/w), the blend concentration of the tocopherol falls within the range of 15 to 85% (w/w), and the phase of the non-aqueous liquid composition changes into a non-lamellar liquid crystal upon contact with water, a phosphate buffer, a body fluid, a lacrimal fluid or a vitreous fluid. | 01-08-2015 |
20140371459 | INDUSTRIAL PROCESS FOR PREPARATION OF 1,2-DIHYDROQUINOLINE DERIVATIVE OR A SALT THEREOF, AND INTERMEDIATE FOR PREPARATION THEREOF - Provided is a method for producing a compound represented by formula (7) or a salt thereof: | 12-18-2014 |
20140243320 | NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY - A compound represented by the following general formula (1) or a salt thereof. R | 08-28-2014 |
20140221306 | OPHTHALMIC SOLUTION COMPRISING DIQUAFOSOL, METHOD FOR PRODUCING THE SAME, AND METHOD FOR INHIBITING FORMATION OF INSOLUBLE PRECIPITATE - Regarding Diquafosol ophthalmic solution comprising a chelating agent, formation of insoluble precipitates found in Diquafosol ophthalmic solution during its storage, as well as deterioration of the filtration performance in the course of production (filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, enhancement of preservative effectiveness has been confirmed. Accordingly, the present invention provides Diquafosol ophthalmic solution having physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient. Particularly in the course of production, the solution can be subjected to efficient filtration sterilization. Moreover, the solution has excellent preservative effectiveness. The present invention also provides a method for inhibiting formation of insoluble precipitates from an aqueous ophthalmic solution comprising diquafosol or a salt thereof, by adding a chelating agent to the solution. | 08-07-2014 |
20140194461 | RAPAMYCIN FORMULATIONS AND METHODS OF THEIR USE - Described herein are liquid rapamycin formulations. Described herein are methods of treating or preventing diseases or conditions, such as choroidal neovascularization, wet AMD and dry AMD, and preventing transition of dry AMD to wet AMD, using the liquid rapamycin formulations described herein. | 07-10-2014 |
20140124542 | Fixed Amount Discharge Container - A fixed amount discharge container includes: a syringe barrel | 05-08-2014 |
20140088039 | OPHTHALMIC SOLUTION CONTAINING HYALURONIC ACID OR SALT THEREOF AND PROPYLENE GLYCOL - An aqueous ophthalmic solution containing hyaluronic acid or a salt thereof at a concentration from 0.03 to 0.5% (w/v) and propylene glycol at a concentration from 0.1 to 1.0% (w/v) comprises as a sole preservative, benzalkonium chloride at a concentration from 0.001 to 0.002% (w/v) and comprises an ionic tonicity agent at such a concentration that an osmotic pressure ratio of the ophthalmic solution becomes from 0.9 to 1.1. | 03-27-2014 |
20140045842 | METHOD FOR TREATING AN INFLAMMATORY DISEASE BY ADMINISTERING A 1,2,3,4-TETRAHYDROQUINOXALINE COMPOUND CONTAINING A PHENYL GROUP HAVING A SULFONIC ACID ESTER STRUCTURE INTRODUCED THEREIN AS A SUBSTITUENT - A method for treating a non-ocular inflammatory disease comprising administering to a patient in need thereof a therapeutically effective amount of a compound represented by the following formula (1) or a salt thereof: | 02-13-2014 |
20130310576 | 3-HYDROXY-6H-BENZO [C] CHROMENE-6-ONE DERIVATIVE AND MANUFACTURING METHOD THEREOF - A method of manufacturing a compound or a salt thereof expressed with a formula (III) below, characterized by causing a compound or a salt thereof expressed with a formula (I) below and a compound or a salt thereof expressed with a formula (II) below to react in the presence of carbonate and copper salt or in the presence of hydroxide salt, carbonate, and copper salt. | 11-21-2013 |
20130275349 | Comprehensive Glaucoma Determination Method Utilizing Glaucoma Diagnosis Chip And Deformed Proteomics Cluster Analysis - Provided is a technique for determining a physiological attribute in a mammal, including the onset or progression of human glaucoma, with high accuracy. The results of the determination of genotype date and the results of the determination of cytokine date are consolidated by a consolidated determination unit ( | 10-17-2013 |
20130226111 | DRUG SUPPORT BODY, AND METHOD FOR PRODUCING SAME - A drug support body is provided that can be used to appropriately administer a drug to the anterior segment of the eye while the production cost is reduced. A drug layer containing a drug component to be administered to an anterior segment of the eye is provided at a halfway portion in a longitudinal direction of a base plate, wherein the base plate includes a bending portion that allows the base plate to bend in a direction opposite to a surface of the base plate on which the drug layer is provided, and by bending the base plate at the bending portion, at least a portion of a surface facing the base plate of the drug layer is exposed from the base plate. | 08-29-2013 |
20130197024 | LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS - Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; non-dispersed mass-forming liquid formulations which form a gel or gel-like substance in an aqueous medium; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration, or placement proximate to a site of a disease or condition to be treated in a subject. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration, or wet age-related macular degeneration in a subject. The liquid formulations may comprise rapamycin or other therapeutic agents. | 08-01-2013 |
20130178524 | PROSTAGLANDIN-CONTAINING PRODUCT - A prostaglandin-containing product including an aqueous liquid preparation containing 16-phenoxy-15-deoxy-15,15-difluoro-17,18,19,20-tetranorprostaglandin F2α, or an alkyl ester or salt thereof, and a resin container containing said aqueous liquid preparation, the resin container being formed from a polymer alloy of polyethylene terephthalate and polyarylate, wherein a component ratio of polyethylene terephthalate/polyarylate is 1/2 to 2/1, thereby inhibiting a decrease of the content of the 16-phenoxy-15-deoxy-15,15-difluoro-17,18,19,20-tetranorprostaglandin F2α or an alkyl ester or salt thereof, in the aqueous liquid preparation. | 07-11-2013 |
20130172287 | AGENT FOR TREATMENT OF DRY EYE CHARACTERIZED BY COMBINING P2Y2 RECEPTOR AGONIST AND HYALURONIC ACID OR SALT THEREOF, METHOD FOR TREATING DRY EYE, AND USE OF THE P2Y2 RECEPTOR AGONIST AND HYALURONIC ACID OR SALT THEREOF - An agent for treatment of dry eye comprising a combination of a P2Y | 07-04-2013 |
20130090359 | METHOD FOR TREATING A TRPV1-MEDIATED DISEASE - A method for treating a TRPV1-mediated disease by administering to a patient a therapeutically effective amount of a compound or a salt thereof having the following formula [I]: | 04-11-2013 |
20130012408 | METHOD FOR DETERMINATION OF ONSET RISK OF GLAUCOMA - A method of determining the presence or the absence of a glaucoma risk by detecting in vitro an allele and/or a genotype of a single nucleotide polymorphism, comparing the allele and/or the genotype detected with at least one of an allele and/or a genotype with a high-risk allele, wherein the presence of a glaucoma risk is determined in a case where the allele detected is the high-risk allele, or the presence of a glaucoma risk is determined in a case where the genotype detected is a homozygote of the genotype comprising the high-risk allele or a heterozygote when the high-risk allele complies with a dominant genetic model, or the presence of a glaucoma risk is determined in a case where the genotype detected is a homozygote of the genotype comprising the high-risk allele when the high-risk allele complies with a recessive genetic model. | 01-10-2013 |
20120329759 | FORMULATIONS AND METHODS FOR VASCULAR PERMEABILITY-RELATED DISEASES OR CONDITIONS - Described herein are formulations and methods for treating, inhibiting, preventing, delaying onset, or causing regression of a disease or condition relating to vascular permeability. | 12-27-2012 |
20120316158 | OPHTHALMIC SOLUTION FOR TREATING OCULAR INFECTION COMPRISING LEVOFLOXACIN OR SALT THEREOF OR SOLVATE OF THE SAME, METHOD FOR TREATING OCULAR INFECTION, LEVOFLOXACIN OR SALT THEREOF OR SOLVATE OF THE SAME, AND USE THEREOF - Instillation of a 1.5% (w/v) levofloxacin ophthalmic solution three times a day, which is the dosage or dose regimen of the present invention, has features to cure bacterial conjunctivitis in a shorter time than instillation of a 0.5% (w/v) ophthalmic solution three times a day, which is the conventional dosage or dose regimen, and not to increase the rate of occurrence of side effects. Curing the ocular infection in a short time leads to shortening of the duration of exposure of the ocular-infection-causing bacterium to levofloxacin. Therefore, the levofloxacin ophthalmic solution in the dosage or dose regimen of the present invention is eventually expected to suppress emergence of the resistant bacterium resulting from the long-term use of the levofloxacin ophthalmic solution in the conventional dosage or dose regimen. In addition, it is confirmed that the levofloxacin ophthalmic solution in the dosage or dose regimen of the present invention directly inhibits the ocular-infection-causing bacterium such as | 12-13-2012 |
20120232119 | METHOD FOR TREATING A KERATOCONJUNCTIVAL DISORDER - A method for treating a keratoconjunctival disorder, wherein the keratoconjunctival disorder comprises at least one disorder selected from the group consisting of a superficial punctate keratopathy, a corneal epithelial defect, corneal erosion, a corneal ulcer, a conjunctival epithelial defect, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis, filamentary keratoconjunctivitis, keratitis and conjunctivitis, and wherein the method comprises orally administering from 3 mg/kg to 30 mg/kg per day of 2-phenyl-1,2-benzisoselenazol-3(2H)-one or a salt thereof to a patient in need thereof. | 09-13-2012 |
20120225817 | THERAPEUTIC AGENT FOR GASTROINTESTINAL DISEASE - The present invention provides a therapeutic agent and a prophylactic agent for a gastrointestinal disease. A peptide having an amino acid sequence represented by Ser-Ser-Ser-Arg or a pharmaceutically acceptable salt thereof promotes wound healing in a gastrointestinal mucosal tissue, and is therefore useful as a therapeutic agent or a prophylactic agent for a gastrointestinal disease. Further, when (a) a peptide having an amino acid sequence represented by Ser-Ser-Ser-Arg or a pharmaceutically acceptable salt thereof and (b) a peptide having an amino acid sequence represented by Phe-Gly-Leu-Met-NH | 09-06-2012 |
20120202817 | COMPOUNDS HAVING 4-PYRIDYLALKYLTHIO GROUP AS A SUBSTITUENT - A compound having the following formula [I] or a pharmaceutically acceptable salt thereof: | 08-09-2012 |
20120202808 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE - A compound of formula (1): | 08-09-2012 |
20120129866 | METHODS FOR PREVENTING OR TREATING METABOLIC DISEASES, INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, ALLERGIC DISEASES, CENTRAL NERVOUS SYSTEM DISEASES, CARDIOVASCULAR DISEASES, HOMEOSTASIS-RELATED DISEASES OR GLAUCOMA - A method for preventing or treating a metabolic disorder, an inflammatory disease, an autoimmune disease, an allergic disease, a central nervous system disease, a cardiovascular disease, a homeostasis-related disease or glaucoma, involving administering a compound or a salt thereof, the compound having the following formula (1) | 05-24-2012 |
20120114637 | MTOR PATHWAY INHIBITORS FOR TREATING OCULAR DISORDERS - Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are ophthalmic formulations that deliver a variety of therapeutic agents, including but not limited to rapamycin (sirolimus), analogs thereof (rapalogs) or other mTOR inhibitors, to a subject for an extended period of time. The ophthalmic formulations may be placed in an aqueous medium of a subject, including but not limited to intraocular or periocular administration, or placement proximate to a site of a disease or condition to be treated in a subject. A method may be used to administer a therapeutic agent to treat or prevent age-related macular degeneration, macular edema, diabetic retinopathy, uveitis, dry eye, or a hyperpermeability disease in a subject. | 05-10-2012 |
20120101046 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR RETINAL DISEASE AND METHOD FOR PROPHYLAXIS OR THERAPY OF RETINAL DISEASE USING JNK (C-JUN AMINO-TERMINAL KINASE) - INHIBITORY PEPTIDE, AND USE OF THE PEPTIDE - Intravitreal administration of a JNK-inhibitory peptide less than 150 amino acids in length, containing at least one D-amino acid, and having (a) a JNK-inhibitory sequence of at least any of SEQ ID NO: 1 and SEQ ID NO: 2, and (b) a transport sequence of at least any of SEQ ID NO: 3 and SEQ ID NO: 4 suppressed spermidine-induced retinal pigment epithelial damage, tunicamycin-induced photoreceptor cell damage, and laser-induced choroidal neovascularization. Thus, the JNK-inhibitory peptide of the present invention is useful for prophylaxis or therapy of a retinal disease. By the use of this JNK-inhibitory peptide, a drug and a method are provided which are capable of preventing or treating a retinal disease even by topical administration to the eye, and use of the JKN-inhibitory peptide for manufacturing the drug is also provided. | 04-26-2012 |
20120040994 | THERAPEUTIC AGENT FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDIN - A therapeutic composition for treating glaucoma or for reducing intraocular pressure containing a combination of pharmaceutically effective amounts of drugs including (i) a Rho kinase inhibitor selected from the group consisting of (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide and 1-(5-isoquinolinesulfonyl)-homopiperazine, or a salt thereof and (ii) a prostaglandin which is latanoprost or a salt of latanoprost, and (iii) optionally a pharmaceutically acceptable carrier. A therapeutic composition for treating glaucoma or for reducing intraocular pressure containing a combination of pharmaceutically effective amounts of drugs comprising (i) a Rho kinase which is (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide or a slat thereof and (ii) a prostaglandin which is isopropyl unoprostone or a salt thereof, and (iii) optionally a pharmaceutically acceptable carrier. | 02-16-2012 |
20120034279 | TRANSSCLERAL DELIVERY - Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include injecting solutions or suspensions adjacent to or within the sclera and implanting solid structures containing the therapeutic agent adjacent to or within the sclera. These methods may be used for administering rapamycin or related compounds to treat choroidal neovascularization associated with age-related macular degeneration. | 02-09-2012 |
20120010288 | Method for protecting a retinal neuronal cell - A method of protecting a retinal neuronal cell by administering an effective amount of a prostaglandin F2α derivative to a patient. A method of preventing or treating an eye disease associated with retinal neuronal cell damage by administering a therapeutically effective amount of a prostaglandin F2α derivative to a patient. | 01-12-2012 |
20110295034 | Eye drop composition containing isopropyl unoprostone - An eye drop composition in which the degradation of isopropyl unoprostone in an eye drop is prevented by adding trometamol to the eye drop containing isopropyl unoprostone. | 12-01-2011 |
20110275632 | Method for preventing or treating a disease related to the glucocorticoid receptor - A method for preventing or treating a disease related to the glucocorticoid receptor involving administering a pharmacologically effective amount of a 1,2-dihydroquinoline compound. | 11-10-2011 |
20110275620 | Method for preventing or treating a disease related to the glucocorticoid receptor - A method for preventing or treating a disease related to the glucocorticoid receptor involving administering a pharmacologically effective amount of a 1,2-hydroquinoline compound. | 11-10-2011 |
20110263638 | Therapeutic agent for glaucoma comprising rho kinase inhibitor and - blocker - A therapeutic agent for glaucoma including a combination of pharmaceutically effective amounts of a Rho kinase inhibitor and a β-blocker, wherein the Rho kinase inhibitor is (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide and the β-blocker is befunolol, carteolol, nipradilol, betaxolol, levobunolol or metipranolol. A method of treating glaucoma including administering effective amounts of a Rho kinase inhibitor and a β-blocker to a patient, wherein the Rho kinase inhibitor is (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide and the β-blocker is befunolol, carteolol, nipradilol, betaxolol, levobunolol or metipranolol. | 10-27-2011 |
20110263589 | Method for preventing or treating a glucocorticoid receptor-related disease - A method of preventing or treating a glucocorticoid receptor-related disease involving administering a therapeutically effective amount of a 1,2-dihydroquinoline compound or a pharmaceutically acceptable salt thereof. | 10-27-2011 |
20110207122 | METHOD FOR DETERMINATION OF PROGRESSION RISK OF GLAUCOMA - A method of determining the presence or the absence of a glaucoma risk, including the steps of detecting in vitro an allele and/or a genotype of a single nucleotide polymorphism which is located on a 31st base of a base sequence, in a sample from a subject, wherein the base sequence is at least one base sequence selected from the group consisting of base sequences shown in SEQ ID NOs: 203 to 752 or a complementary sequence thereto (step A), and comparing the allele and/or the genotype detected in the step A with at least one of an allele and/or a genotype, containing a high-risk allele, in the base sequences shown in SEQ ID NOs: 203 to 752 (step B). According to the method of the present invention, the level of a progressive risk of glaucoma in a sample donor can be determined by analyzing an allele or a genotype of a single nucleotide polymorphism in the present invention in the sample, so that the sample donor can take a preventive measure of glaucoma, or can receive appropriate treatments, on the basis of this risk. | 08-25-2011 |
20110201655 | PHARMACEUTICAL COMPOSITION IMPROVING INTESTINAL ABSORPTION - An object of the present invention is to provide a pharmaceutical composition that improves intestinal absorption of a compound having a structure represented by the general formula [1]. The composition containing a compound represented by the general formula [1] or a salt thereof and (b) a lipophilic substance improves intestinal absorption of the compound. In the formula, A represents —(NR | 08-18-2011 |
20110195428 | COMPOSITION, KIT, AND METHOD FOR ASSAYING AGEING AND DISEASE ACCOMPANIED WITH VASCULAR DISORDER - The present invention relates to a method for detecting an ageing or a disease accompanied with a vascular disorder such as age-related macular degeneration, comprising measuring one or more of polypeptides comprising any of amino acid sequences shown in SEQ ID NOS: 1 to 21, mutants thereof, or fragments thereof in a biological sample from a subject, and also to a composition or kit for diagnosing an ageing or a disease accompanied with a vascular disorder such as age-related macular degeneration. | 08-11-2011 |
20110166151 | GLUCOCORTICOID RECEPTOR AGONIST COMPRISING 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVES CONTAINING PHENYL GROUP HAVING SULFONIC ACID ESTER STRUCTURE INTRODUCED THEREIN AS SUBSTITUENT - The object aims to find a novel pharmacological activity of a novel 1,2,3,4-tetrahydroquinoxaline derivative which contains, as a substituent, a phenyl group having a sulfonic acid ester structure introduced therein. A compound represented by general formula (1) or a salt thereof is useful as a glucocorticoid receptor agonist, particularly as a therapeutic agent for diseases against which a glucocorticoid receptor agonist (e.g., a steroid) is believed to be effective, such as inflammatory bone/joint diseases, inflammatory ophthalmic diseases (inflammatory ophthalmic diseases in the anterior or posterior segment of an eye). R | 07-07-2011 |
20110160267 | Method of treating diabetic retinopathy - A method for treating diabetic retinopathy involving topically administering to an eye of a patient a pharmacologically effective amount of a compound represented by the following formula [II] or a salt thereof: | 06-30-2011 |
20110160262 | Method of treating retinal vein occlusion - A method for treating retinal vein occlusion involving administering to a patient a pharmacologically effective amount of a compound represented by the following formula (II) or a salt thereof: | 06-30-2011 |
20110152264 | METHOD AND COMPOSITION FOR TREATING OCULAR HYPERTENSION AND GLAUCOMA - The present invention relates to an ophthalmic aqueous composition containing PGF2α analogues for treating ocular hypertension and glaucoma, to a method for treating ocular hypertension and glaucoma by administering said composition to a subject in need of such treatment, and to a method for increasing aqueous solubility and stability of PGF2α analogues in an aqueous composition. | 06-23-2011 |
20110124668 | NOVEL INDOLE DERIVATIVE HAVING, CARBAMOYL GROUP, UREIDO GROUP AND SUBSTITUTED OXY GROUP - The present invention relates to synthetic studies on novel indole derivatives having a carbamoyl group, a ureido group and a substituted oxy group or a salt thereof, and pharmaceutical actions of the derivatives. The compound and a salt thereof represented by the general formula (1) has an IKKβ inhibitory activity and is useful as a preventive and/or therapeutic agent for diseases considered to be associated with IKKβ. In the formula, R | 05-26-2011 |
20110124646 | Novel cyclic compound having pyrimidinylalkylthio group - A method of treating a disease associated with angiogenesis by administering a therapeutically effective amount of a compound represented by the formula (1) or a salt thereof | 05-26-2011 |
20110124009 | COMPOSITION, KIT AND METHOD FOR ASSAYING NEUROPATHY - The present invention relates to a method for detecting a disease accompanied with neuropathy such as glaucoma, comprising measuring and/or detecting one or more of polypeptides shown in SEQ ID NOS: 1 to 15, mutants thereof, or fragments thereof in a biological sample from a subject, and also to a composition or kit for diagnosis of a disease accompanied with neuropathy such as glaucoma. | 05-26-2011 |
20110118348 | Methods of stabilizing latanoprost in an aqueous solution - A method of stabilizing latanoprost in an ophthalmic solution containing 0.005% (W/V) of latanoprost to be stored to be stored at room temperature (i) by adding 0.1 to 2% (W/V) of ε-aminocaproic acid to the solution or (ii) by adding 0.1 to 2% (W/V) of ε-aminocaproic acid and adjusting the pH of the solution to 5.0 to 6.25. | 05-19-2011 |
20110092524 | Agent for Enhancing Corneal Epithelial Barrier Function - The invention relates to a pharmacological action of a compound which functions as a PPARγ agonist on the barrier function of the corneal epithelium. A PPARγ agonist such as rivoglitazone, DRF-2593, GW-544 or BMS-298585 exhibits an excellent effect of enhancing the corneal epithelial barrier function in a test for enhancement of corneal epithelial barrier function, and therefore is useful as a preventive agent or a therapeutic agent for ocular infection or ocular unidentified complaint caused by a decrease in the corneal epithelial barrier function. Further, the PPARγ agonist can enhance the corneal epithelial barrier function of diabetic patients, patients with decreased corneal epithelial barrier function due to aging and patients who underwent refractive surgery such as PRK (photorefractive keratectomy) or LASIK (laser in situ keratomileusis) or cataract surgery. | 04-21-2011 |
20110077244 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE - The present invention relates to synthetic studies of a novel thiophenediamine derivative having a urea structure and to finding pharmaceutical actions thereof. The present invention provides a compound represented by the following general formula (1) or a salt thereof. In the formula (1), R | 03-31-2011 |
20110059897 | Methods for treating a skin wound - A therapeutic method for treating a skin wound involving administering to a patient in need thereof a composition containing pharmaceutically effective amounts of the following components: (1) a peptide consisting of the amino acid sequence represented by Ser-Ser-Ser-Arg (SEQ ID NO: 1) or pharmaceutically acceptable salts thereof and (2) a peptide consisting of the amino acid sequence represented by Phe-Gly-Leu-Met-NH | 03-10-2011 |
20110039891 | Methods for treating a disease in which Rho kinase is involved - A method for treating a disease in which Rho kinase is involved. The method is carried out by administering to a patient in need thereof a pharmaceutically effective amount of a compound of the following formula or a pharmaceutically acceptable salt thereof: | 02-17-2011 |
20100331407 | Clear ophthalmic solution comprising latanoprost as active ingredient - A clear ophthalmic solution containing latanoprost having a concentration of 0.005% (W/V), 0.003 to 0.01% (W/V) benzalkonium chloride and at least one agent selected from the group consisting of glycerin, polyethylene glycol, propylene glycol and trehalose, wherein the agent is in a concentration to make the solution isotonic. A method of preventing white turbidity in an ophthalmic solution containing latanoprost having a concentration of 0.005% (W/V) and 0.003 to 0.01% (W/V) benzalkonium chloride, the method involving adding to the solution at least one agent selected from the group consisting of glycerin, polyethylene glycol, propylene glycol and trehalose, wherein the agent is in a concentration to make the solution isotonic. | 12-30-2010 |
20100317615 | Method of enhancing ocular penetration of a drug in an eyedrop - A method of enhancing ocular penetration of a drug in an eyedrop by administering to an eye, an eyedrop containing, particulate agar having a weight-average molecular weight of from 5,000 to 1,200,000, the particulate agar being obtained by dissolving agar into an aqueous solution by heating and then cooling the resultant mixture to avoid gelling, while applying a stress by vibration, shearing, stirring, compression or pulverizing, wherein the particulate agar is in an amount of 0.1 to 10 wt %. | 12-16-2010 |
20100196895 | METHOD FOR DETERMINATION OF ONSET RISK OF GLAUCOMA - A method of determining the presence or the absence of a glaucoma risk, including the steps of detecting in vitro an allele and/or a genotype of a single nucleotide polymorphism which is located on a 31st base of a base sequence, in a sample from a subject, wherein the base sequence is at least one base sequence selected from the group consisting of base sequences shown in SEQ ID NOs: 203 to 514 or a complementary sequence thereto (step A), and comparing the allele and/or the genotype detected in the step A with at least one of an allele and/or a genotype, containing a high-risk allele, in the base sequences shown in SEQ ID NOs: 203 to 514 (step B). According to the method of the present invention, the level of an onset risk of glaucoma in a sample donor can be determined by analyzing an allele or a genotype of a single nucleotide polymorphism in the present invention on the sample, so that the sample donor can take a preventive measure of glaucoma, or can receive appropriate treatments, on the basis of this risk. | 08-05-2010 |
20100137307 | NOVEL 1,2,3,4,-TETRAHYDROQUINOXALINE DERIVATIVE WHICH HAS, AS SUBSTITUENT, PHENYL GROUP HAVING SULFONIC ACID ESTER STRUCTURE OR SULFONIC ACID AMIDE STRUCTURE INTRODUCED TEREIN AND HAS GLUCOCORTICOID RECEPTOR-BINDING ACTIVITY - The compounds represented in general formula (1) or a salt thereof are useful for glucocorticoid receptor modulators. In the formula, R | 06-03-2010 |
20100099675 | NOVEL PYRROLE DERIVATIVE HAVING UREIDO GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS - Objects of the present invention are to study on the synthesis of a novel pyrrole derivative having a ureido group and an aminocarbonyl group as substituents or a salt thereof, to find a pharmacological effect of the derivative or a salt thereof, and to find a medicinal agent which has a prophylactic and/or therapeutic effect on a retinal disease or the like through oral administration. A compound represented by the general formula (1) or a salt thereof has an inhibitory activity against the production of interleukin-6 and/or an inhibitory effect on choroidal neovascularization, and is therefore useful as a prophylactic and/or therapeutic agent for a disease associated with interleukin-6, an ocular inflammatory disease and/or a retinal disease. In the formula, the ring A represents a benzene ring or the like; R | 04-22-2010 |
20100063060 | Therapeutic agent for glaucoma comprising Rho Kinhase inhibitor and prostaglandin - A combination of a Rho kinase inhibitor and a prostaglandin as a therapeutic agent for treating glaucoma. The actions of reducing intraocular pressure are complemented and/or enhanced by combining a Rho kinase inhibitor with a prostaglandin. Each of the Rho kinase inhibitor and the prostaglandin can be administered in combination or in a mixture. | 03-11-2010 |
20100063045 | NOVEL PYRIDINECARBOXYLIC ACID (2-AMINOPHENYL) AMIDE DERIVATIVE HAVING UREA STRUCTURE - Objects of the present invention are to study the synthesis of a novel pyridinecarboxylic acid (2-aminophenyl)amide derivative having a novel urea structure and to find a pharmacological effect of the derivative. The invention provides a compound represented by the formula (1) or a salt thereof. In the formula, R | 03-11-2010 |
20100056522 | INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT - An object of the present invention is to find a novel pharmacological effect of a compound having an HDAC inhibitory effect. The compound having an HDAC inhibitory effect of the invention has an excellent effect of cell morphological change on trabecular meshwork cells and/or effect of intraocular pressure reduction, and is therefore useful as a preventive and/or therapeutic agent for a disease considered to be associated with aqueous humor circulation and/or intraocular pressure, particularly as a preventive and/or therapeutic agent for glaucoma or ocular hypertension. | 03-04-2010 |
20100041671 | Methods for treating glaucoma - A method for treating glaucoma comprising administering to a patient pharmaceutically effective amounts of a Rho kinase inhibitor and a prostaglandin. | 02-18-2010 |
20100016380 | TNF-alpha production inhibitors - A compound having the following formula | 01-21-2010 |
20090286786 | Compounds having a 4-pyridylalkylthio group as a substituent - A compound having the following formula [I] or a pharmaceutically acceptable salt thereof: | 11-19-2009 |
20090253765 | Angiogenesis Inhibitor Containing Amine Derivative as Active Ingredient - An object of the present invention is to provide an angiogenesis inhibitor. The angiogenesis inhibitor according to the present invention contains a compound represented by the following general formula [I] or a salt thereof as an active ingredient. In the formula, the ring A represents a benzene ring or a naphthalene ring; X represents a single bond, an alkylene group or —CH | 10-08-2009 |
20090198213 | METHOD OF OPHTHALMIC SURGERY AND KIT THEREFOR - A method of micro-incision ophthalmic surgery, comprising, in the order mentioned, the steps of: | 08-06-2009 |
20090111807 | Novel 1,2,3,4-Tetrahydroquinoxaline Derivative Having Glucocorticoid Receptor Binding Activity - An object of the present invention is to synthesize a novel 1,2,3,4-tetrahydroquinoxaline derivative represented by formula (1) and to find a pharmacological action of the derivative. In the formula, the R | 04-30-2009 |
20090042962 | Therapeutic Agent for Keratoconjunctival Disorder - An object of the present invention is to research a therapeutic agent for a keratoconjunctival disorder. A compound represented by the following general formula (1) or a salt thereof exhibits an excellent improving effect on corneal disorder models, and therefore is useful as a therapeutic agent for a keratoconjunctival disorder such as dry eyes, corneal ulcer, keratitis or conjunctivitis. In the formula, the ring Y represents a substituted or unsubstituted nitrogen-containing heterocyclic ring; R | 02-12-2009 |
20090036552 | Noninvasive Drug Delivery System To Tissue of Posterior Segment of Eye Using Solid Composition - The present invention provides a drug delivery system by noninvasive administration, which is excellent in drug transfer to a tissue of the posterior segment of the eye via a local eye tissue. By administering a solid composition comprising a drug and a mucoadhesive substance having an adhesion strength of from 200 to 1000 g in the conjunctival sac, a drug delivery system excellent in drug transfer to a tissue of the posterior segment of the eye via a local eye tissue can be constructed. | 02-05-2009 |
20090005317 | Methods for treating a corneal disorder and promoting skin wound healing - A method for treating a corneal disorder or for promoting skin wound healing comprising administering to a patient in need thereof a composition containing pharmaceutically effective amounts of (i) a first peptide comprising an amino acid sequence containing the following consecutive amino acids: Ser-Ser-Ser-Arg (SEQ ID NO: 1), or an analog thereof or a pharmaceutically acceptable salt thereof and (ii) a second peptide comprising an amino acid sequence containing the following consecutive amino acids with a terminal —NH | 01-01-2009 |
20080269353 | Preventative Composition For Ophthalmic Use - An object of the present invention is to prevent the generation of chlorine dioxide in a liquid preparation for ophthalmic use containing a chlorite. A liquid preparation for ophthalmic use containing a preservative composition for ophthalmic use comprising a chlorite and at least one stabilizer selected from the following 1) to 7): 1) creatinine; 2) geraniol; 3) glucose; 4) tocopherol acetate; 5) oxyquinoline sulfate; 6) a sugar alcohol; and 7) a polyoxyethylene sorbitan fatty acid ester can prevent the generation of chlorine dioxide, and is therefore excellent in safety and exhibits a sustained preservative effect for a prolonged period of time. | 10-30-2008 |
20080199524 | Eyedrops containing particulate agar - It is intended to prepare a composition which contains polysaccharide at a high concentration and yet remains in the state of a liquid having low viscosity to thereby provide drugs, eyedrops, foods, cosmetics, toiletry products having a novel texture or function. The composition in the state of a liquid having low viscosity is obtained by heating polysaccharide at a high concentration in a water-containing liquid and then cooling under applying a shear force, which enables the provision of the above-described drugs. The composition is usable as an aqueous drug vehicle which is free from gelling due to temperature changes during storage and easily applied without pouring and/or streaming down. Eyedrops containing agar have an effect of enhancing ocular drug penetration. Eyedrops containing particulate agar maintain a low viscosity and, achieve easy instillation and impart a favorable feel in instillation. | 08-21-2008 |